Nephroblastoma Stem Cell Therapy Development

The most frequent renal tumor in children is nephroblastoma, which typically manifests as an abdominal pathology. The disease was described in detail pathologically by Wilms in 1899 and, therefore, was also named Wilms' tumor. Although multimodal therapy has made recent strides, treating neuroblastoma is still a clinical challenge. CD BioSciences has launched a development service for nephroblastoma stem cell therapies, dedicated to advancing the treatment of this disease.

Overview of Nephroblastoma

Nephroblastoma develops in the renal parenchyma after beginning in the embryo, grows with a distorted form, and then invades the kidney tissue nearby. The cure rate for pediatric nephroblastoma is high, but no effective combination therapy has been explored to date for adult patients with advanced nephroblastoma. And, patients with nephroblastoma continue to run the risk of the disease returning and spreading after treatment. It is crucial to comprehend how nephroblastoma arises and progresses as well as look for novel therapeutic targets and approaches. Numerous cancer types have been shown to progress when micro RNAs (miRs) are expressed abnormally. It is therefore likely to be a new target for the treatment of cancer.

Normal kidney development and processes affected by WT predisposing lesions. (Bhutani N, et al., 2021)

Basis about miRNAs

Small, single-stranded, non-coding RNA molecules called microRNA (miRNA) have 21 to 23 nucleotides. Numerous mammalian cell types and extracellular circulating miRNAs are rich in miRNAs. Circulating miRNAs can serve as biomarkers for a variety of diseases because they are released into bodily fluids like blood and cerebrospinal fluid. Numerous pieces of evidence suggest that miRNAs play a role in the regulation of various cellular processes, such as cell division, proliferation, and apoptosis. Additionally, it has been demonstrated that aberrant miRNA expression contributes to the emergence and spread of a number of tumor types. Promising biomarkers and therapeutic targets for the treatment of cancer include miRNAs.

Nephroblastoma Marker miR-130b-3p

MiR-130b is a tumor suppressor or oncogenic factor that exhibits dysregulation in a number of cancers, including gliomas, gastric cancers, and endometrial cancers. MiR-130b-3p was found to be highly expressed in nephroblastoma tissues taken from children who had the disease, according to studies. Phosphatase and tensin homolog, a target of miRNAs, was used for miR-130b analysis, and it was discovered that this target was downregulated in nephroblastoma.  And PTEN-small interfering RNA was able to reverse all of miR-130b-3p's effects on nephroblastoma cells. Further investigation revealed that miR-130b-3p inhibitor could significantly inhibit Akt/NF-B/Survivin signaling, induce apoptosis, and reduce cell proliferation in nephroblastoma cells.

Our Services

CD BioSciences offers nephroblastoma stem cell therapy development services. It has been shown that miR-130b-3p may be a valuable clinical biomarker and therapeutic target for nephroblastoma. However, there is still a long way to go before clinical application, and new strategies and theoretical basis for the treatment of nephroblastoma are needed. Based on our professional laboratory team, we can contribute to the development of stem cell therapy for nephroblastoma.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

References

1. Hu, Y. et al. (2019). Aberrant expression and mechanism of mir130b3p/phosphatase and tensin homolog in nephroblastoma in children. Experimental and Therapeutic Medicine. 18(2).
2. Bhutani N, Kajal P, Sharma U. Many faces of Wilms Tumor: Recent advances and future directions. Ann Med Surg (Lond). 2021 Mar 7;64:102202.